Gerresheimer's Legal and Liquidity Crisis Deepens Amid Information Blackout

Pharma packager Gerresheimer is under legal and financial pressure. A shareholder group pursues damages, audits delay reports, and SDAX delisting triggers sell-offs, with shares down 66% in a year.

The pressure on pharmaceutical packaging supplier Gerresheimer is intensifying from multiple fronts. While its shares saw a brief 4.7 percent rally to EUR 17.44 on Tuesday, this provides little solace for investors trapped in a prolonged information vacuum. The company remains without audited financial statements, and a major shareholder association is now pursuing legal action against former executives.

Germany's leading shareholder advocacy group, DSW, is examining concrete claims for damages against former members of Gerresheimer's management board. The investigation centers on potential breaches of duty linked to so-called "bill-and-hold" agreements, where revenue may have been booked before goods physically left the warehouse. This legal move adds a significant new dimension to the company's existing operational and financial turmoil.

At the heart of the ongoing crisis is a second external audit firm currently scrutinizing business transactions from 2024 and 2025. This special audit is taking longer than initially planned, creating a domino effect on the company's reporting. The delay means the audited annual report for 2025 is missing, and the Q1 2026 figures, originally scheduled for April 16, have been postponed indefinitely. A new date will only be set once the audit findings are complete. Interim CEO Uwe Röhrhoff aims to present the annual report in June 2026.

The regulatory scope has widened considerably. Beyond the questionable revenue bookings, the German financial watchdog, BaFin, is also examining leasing liabilities, asset impairments in the triple-digit million-euro range within the Advanced Technologies segment, and risks surrounding the acquisition of Bormioli Pharma.

Operationally, management is taking drastic steps to shore up the business. The glass plant in Chicago will be shut down by the end of 2026, with production shifting to Italy and India. The company anticipates non-cash impairment charges of up to EUR 240 million for the current fiscal year as a result. While this move is intended to stabilize margins long-term, it comes after a period of weak market growth and a high debt burden.

Concurrently, Gerresheimer faces structural selling pressure in the markets. Since April 10, the company is no longer a member of the SDAX. Deutsche Börse ejected the packaging specialist for failing to submit its annual report by the March 31 deadline, replacing it with the Bulgarian provider Shelly Group. This exclusion forces passively managed ETFs that track the SDAX to divest their holdings, accelerating the sell-off witnessed in recent weeks.

The financial damage to shareholders has been severe. Since the start of the year, the stock has lost approximately 37 percent of its value. Over a twelve-month horizon, the decline is roughly 66 percent, leaving the share price nearly 73 percent below its 52-week high of EUR 64.40.

With audited accounts absent, the company's immediate future hinges on critical negotiations with its creditors. Management is currently in talks with lenders to secure extensions and adjustments to financial covenants, aiming to avert a technical default.

The entire reporting calendar remains in limbo. The half-year report is tentatively slated for July 14, 2026, and the Q3 statement for October 15. Whether these dates hold depends entirely on the progress of the special audit. If the annual report arrives in June as promised, a return to a regular reporting cycle—and a potential reinstatement into Deutsche Börse indices—could become feasible. Any further delay would push back these milestones and extend the current information blackout, leaving institutional investors without a foundation for a fundamental reassessment for at least another two months.